Skip to main content

Table 1 Clinical features of the WT TARGET cohort

From: Downregulated TICAM1 is a prognostic biomarker and associated with immune tolerance of Wilms tumor patients

  TARGET(N = 126)
Gender
 Female 70(55.56%)
 Male 56(44.44%)
Age
  < 3 years 33(26.19%)
  > 3 years 93(73.80%)
Stage
 I-II 68(53.97%)
 III-IV 58(46.03%)
Evenet
 Relapse/progression 101(80.06%)
 None 25(19.84)
TICAM1
 High-expression` 51(40.48%)
 Low-expression 75(59.52%)